Ebrantil, 5 mg/ml 5 pcs

The drug Ebrantil reduces BP and BP in a balanced manner, reducing peripheral resistance.

Urapidil reduces pre- and post-load on the heart, increases the efficiency of the heart contraction, thus, in the absence of arrhythmia, the drug increases the reduced cardiac output.

The mechanism of action. The drug Ebrantil has central and peripheral mechanisms of action.

Predominantly blocks peripheral postsynaptic α₁-adrenoreceptors, i.e. the drug blocks vasoconstrictor action of catecholamines.

In the CNS, urapidil affects the activity of the vasomotor center, which is manifested in the prevention of reflex changes in the tone of the sympathetic nervous system.

Urapidil does not affect parameters of carbohydrate metabolism, uric acid metabolism and does not cause fluid retention in the body.

Indications

Active ingredient

Composition

1 ml of solution for intravenous administration contains:

the active ingredient:

Urapidyl hydrochloride 5.47 mg (corresponding to 5 mg of urapidyl),

excipients:

propylene glycol;

sodium hydrophosphate dihydrate;

sodium dihydrophosphate dihydrate;

water for injection

How to take, the dosage

Inject by injection or by prolonged infusion in the supine position.

Hypertensive crisis, severe arterial hypertension, refractory hypertension

1. Intravenous: 10-50 mg of Ebrantil is slowly administered under BP control. Decrease of BP is expected within 5 min after injection. Depending on the therapeutic effect, Ebrantil may be administered again.

2. intravenous drip or continuous infusion using a perfusion pump. The maintenance dose is an average of 9 mg/h, i.e. 250 mg of Ebrantil (10 ampoules of 5 ml or 5 ampoules of 10 ml) in 500 ml of infusion solution (1 mg = 44 drops = 2.2 ml).

The maximum allowable ratio is 4 mg of Ebrantil per 1 ml of the infusion solution.

The recommended maximum initial rate is 2 mg/min.

The drip infusion rate depends on the patient’s BP.

The drip infusion solution for BP maintenance is prepared as follows.

Overly 250 mg of the drug (10 5 ml ampoules or 5 10 ml ampoules) of Ebrantil is added to 500 ml of a solution for infusion, such as physiological solution or 5 or 10% dextrose (glucose) solution.

If a perfusion pump is used to administer a maintenance dose, 100 mg (4 vials of 5 ml or 2 vials of 10 ml) of Ebrantil is put into the syringe of the perfusion pump and diluted to 50 ml with saline, 5 or 10% dextrose (glucose) solution.

Controlled (controlled) reduction of BP when it increases during and/or after surgery. Continuous infusion with a perfusion pump or drip infusion is used to maintain BP at the level achieved with an IV infusion.

The dosing regimen is shown in the figure.

Notes:

If other hypotensive medications have been used previously, Ebrantil, can only be administered after a period of time long enough for the previously administered medication(s) to work; the dose of Ebrantil should be adjusted accordingly;

– caution must be exercised when using hypotensive agents in elderly patients; the starting dose should be lowered compared to the recommended dose, because the sensitivity in elderly patients to these drugs is often altered (Vd is reduced and T1/2 is increased).

The drug may be injected once or repeatedly. Injection of the drug may be combined with a subsequent drip infusion. Parenteral therapy may be repeated if there is a new increase in BP.

Interaction

The hypotensive effect of urapidil may be enhanced when co-administered with α-adreno-blockers or other hypotensive agents, as well as with hypovolemia (nausea, vomiting) and when taking ethanol.

Concomitant administration of cimetidine may increase Cmax of urapidil in plasma by 15%.

Special Instructions

Combined use with other orally prescribed hypotensive agents is possible.

There are no clinical data on the use of the drug in children under 18 years of age.

Contraindications

With caution: advanced age, impaired liver and/or renal function, hypovolemia.

Side effects

Most of the following side effects are due to a rapid drop in BP, but clinical experience has shown that they disappear within minutes, even after a drip infusion of Ebrantil. Severe side effects may require discontinuation of treatment.

Lists of side effects with an indication of their frequency are presented in the tables.

Side effects of the drug Ebrantil (solution for intravenous injection)

Overdose

Symptoms: dizziness, orthostatic collapse, fatigue, lethargy.

Treatment: in case of a sharp drop in BP, the patient should be elevated and infusion therapy should be started to increase the RBC. If these measures are ineffective, vasoconstrictor infusion under BP control may be initiated. In very rare cases, catecholamines (0.5-1 mg of epinephrine (adrenaline) diluted in 10 ml of physiological solution) should be administered intravenously.